TNF-α inhibitors and other biologic agents for the treatment of immune checkpoint inhibitor-induced myocarditis
X Liu, W Wu, L Fang, Y Liu, W Chen - Frontiers in Immunology, 2022 - frontiersin.org
With anti-PD-1 antibodies serving as a representative drug, immune checkpoint inhibitors
(ICIs) have become the main drugs used to treat many advanced malignant tumors …
(ICIs) have become the main drugs used to treat many advanced malignant tumors …
Multiple faces of multiple sclerosis in the era of highly efficient treatment modalities: Lymphopenia and switching treatment options challenges daily practice
AG Vakrakou, ME Brinia, A Alexaki… - International …, 2023 - Elsevier
The expanded treatment landscape in relapsing-remitting multiple sclerosis (MS) has
resulted in highly effective treatment options and complexity in managing disease-or drug …
resulted in highly effective treatment options and complexity in managing disease-or drug …
Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study
P Kazakou, D Tzanetakos, AG Vakrakou… - Clinical and …, 2023 - Springer
Autoimmune thyroid disease (AITD) is the most common adverse effect in alemtuzumab
(ALZ) treated relapsing–remitting (RR) multiple sclerosis (MS) patients. The objective of this …
(ALZ) treated relapsing–remitting (RR) multiple sclerosis (MS) patients. The objective of this …
Mycobacterium avium subsp. paratuberculosis Antigens Elicit a Strong IgG4 Response in Patients with Multiple Sclerosis and Exacerbate Experimental Autoimmune …
D Cossu, Y Tomizawa, K Yokoyama, T Sakanishi… - Life, 2023 - mdpi.com
Neuroinflammation can be triggered by microbial products disrupting immune regulation. In
this study, we investigated the levels of IgG1, IgG2, IgG3, and IgG4 subclasses against the …
this study, we investigated the levels of IgG1, IgG2, IgG3, and IgG4 subclasses against the …